Wexford Capital’s Biogen BIIB Stock Holding History

Wexford Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-725	Closed	-$207K	–	191
2023 Q2	$207K	Buy	+725	New	+$216K	0.04%	179
2017 Q3	–	Sell	-1,300	Closed	-$353K	–	151
2017 Q2	$353K	Buy	+1,300	New	+$344K	0.03%	134
2016 Q3	–	Sell	-18,558	Closed	-$4.49M	–	161
2016 Q2	$4.49M	Sell	18,558 -591	-3%	-$156K	0.78%	44
2016 Q1	$4.99M	Sell	19,149 -1,703	-8%	-$450K	0.97%	37
2015 Q4	$6.39M	Sell	20,852 -32,953	-61%	-$9.47M	1.5%	23
2015 Q3	$15.7M	Buy	+53,805	New	+$17.8M	3.04%	7
2014 Q4	–	Sell	-7,200	Closed	-$2.38M	–	61
2014 Q3	$2.38M	Buy	+7,200	New	+$2.37M	0.22%	59
2014 Q1	–	Sell	-2,300	Closed	-$643K	–	183
2013 Q4	$643K	Buy	2,300 +1,000	+77%	+$259K	0.06%	138
2013 Q3	$313K	Sell	1,300 -2,700	-68%	-$604K	0.03%	175
2013 Q2	$861K	Buy	+4,000	New	+$855K	0.08%	119

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wexford Capital's BIIB Position: Q3 2023 in Review

Wexford Capital sold out of Biogen (BIIB) in Q3 2023, closing a stake of 725 shares — an estimated $207K sold.

Wexford Capital first reported a position in BIIB in Q2 2013 and held it in 10 quarters. The position peaked at $15.7M in Q3 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Wexford Capital reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Wexford Capital sold 725 Biogen shares in Q3 2023, an estimated $207K.
Wexford Capital first reported a position in Biogen in Q2 2013 and held it in 10 quarters.
Wexford Capital's Biogen position peaked at $15.7M in Q3 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Wexford Capital's 13F filing for Q3 2023, filed 14 Nov 2023.